Although interferon beta (IFN-β) therapies have been commonly used as a treatment for multiple sclerosis (MS) for over a decade, the mechanism of action (MOA) of these therapeutic agents remains largely undefined [1,2]. Here, IFNB1 is linked to myeloid sarcoma.